Tau protein phosphorylated at threonine-231 is expressed abundantly in the cerebellum in prion encephalopathies

Manuscript Number: 

20-1308R2

Author(s): 
Marely Bravo-Muñoz, Linda Garcés-Ramírez, Parménides Guadarrama-Ortíz, Víctor Manuel Gómez-López, Charles R. Harrington, Mario Hernandes-Alejandro, José Luna-Muñoz, Sandra Martínez-Robles, Francisco Montiel-Sosa, Miguel Ángel Ontiveros-Torres, Mar Pacheco-Herrero, Ignacio Villanueva-Fierro, Amparo Viramontes-Pintos, Petra Yescas, Fidel de la Cruz

Disclosures

Marely Bravo-Muñoz

  • Nothing to Disclose

Fidel de la Cruz

  • Nothing to Disclose

Linda Garcés-Ramírez

  • Nothing to Disclose

Víctor Manuel Gómez-López

  • Nothing to Disclose

Parménides Guadarrama-Ortíz

  • Nothing to Disclose

Charles R. Harrington

  • Equity:
    I own equity in TauRx Therapeutics Ltd.
    Patents/Royalties
    I am Chief Scientific Officer at TauRx Therapeutics Ltd, and its affiliate WisTa Laboratories Ltd. I am an inventor on a number of patents in the field of Tau protein and neurodegenerative disorders owned by WisTa Laboratories Ltd. These companies have no role in the sponsorship or in the content of the present manuscript.

Mario Hernandes-Alejandro

  • Nothing to Disclose

José Luna-Muñoz

  • Nothing to Disclose

Sandra Martínez-Robles

  • Nothing to Disclose

Francisco Montiel-Sosa

  • Nothing to Disclose

Miguel Ángel Ontiveros-Torres

  • Nothing to Disclose

Mar Pacheco-Herrero

  • Nothing to Disclose

Ignacio Villanueva-Fierro

  • Nothing to Disclose

Amparo Viramontes-Pintos

  • Nothing to Disclose

Petra Yescas

  • Nothing to Disclose